NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
June 08 2020 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology
company focused on discovering and developing transformative
therapeutics for patients, today announced the appointment of
Carole Ho, M.D. to its Board of Directors. Dr. Ho currently serves
as Chief Medical Officer and Head of Development at Denali
Therapeutics.
“Carole’s background as a physician-scientist with
deep industry expertise is ideally suited to NGM’s culture and
vision, and we are thrilled to welcome her to our Board,” said
David J. Woodhouse, Ph.D., NGM’s Chief Executive Officer. “We
continue to advance aldafermin, our lead candidate for the
treatment of non-alcoholic steatohepatitis, or NASH, toward
late-stage development and commercialization. Simultaneously, we
are progressing clinical programs in oncology and ophthalmology,
including NGM621, our anti-complement C3 antibody program for
geographic atrophy. Given Carole’s experience spanning early- to
late-stage clinical development, we look forward to her insights as
we design and execute our late-stage NASH clinical development
program and other clinical programs and translate various exciting,
novel early-stage opportunities into viable clinical development
candidates.”
Dr. Ho commented, “NGM has carved out a prominent
position in the NASH development landscape with aldafermin. In
addition, powered by its deep biologics and biology research
engine, coupled with a strong clinical development infrastructure,
NGM has built a pipeline that extends well beyond NASH. It takes
creativity and a thoughtful strategy, particularly for an emerging
growth company, to nurture clinical programs to fruition in
multiple therapeutic areas. I look forward to working with David,
my fellow NGM board members and the NGM team to maximize the
breadth of opportunities for NGM and, in turn, for patients.”
In her role as Chief Medical Officer and Head of
Development at Denali since 2015, Dr. Ho has built an integrated
development organization that is responsible for guiding
therapeutic candidates from pre-IND enabling studies through to
ultimate approval. Prior to joining Denali, Dr. Ho served as Vice
President of Early Clinical Development at Genentech, where she was
responsible for the delivery of pivotal trial-ready therapeutic
candidates for all non-oncology indications, including
CV-metabolism, ophthalmology, neurology, infectious disease,
respiratory, rheumatology and gastroenterology. During her eight
years at Genentech, Dr. Ho held several senior leadership roles
across multiple early- and late-stage clinical programs in various
therapeutic areas. Earlier in her career, Dr. Ho served as a
visiting scientist at Genentech in the laboratory of Marc
Tessier-Lavigne, Ph.D., and also as a Faculty Member in the
Department of Neurology at Stanford University.
Dr. Ho completed her residency in neurology at
Harvard Medical School at the Massachusetts General Hospital /
Brigham and Women’s Hospital, where she served as Chief Resident.
She earned her M.D. from Cornell University and her B.S. in
biochemical sciences from Harvard College. In addition to her
appointment to NGM’s Board, Dr. Ho also serves on the Board of
Directors of Beam Therapeutics.
About NGM Biopharmaceuticals,
Inc.
NGM is a biopharmaceutical company focused on
discovering and developing novel therapeutics based on scientific
understanding of key biological pathways underlying
cardio-metabolic, liver, oncologic and ophthalmic diseases. We
leverage our biology-centric drug discovery approach to uncover
novel mechanisms of action and generate proprietary insights that
enable us to move rapidly into proof-of-concept studies
and deliver potential first-in-class medicines to
patients. At NGM, we aspire to operate one of the most productive
research and development engines in the biopharmaceutical industry,
with multiple programs in clinical development. Visit us
at www.ngmbio.com for more information.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “look
forward,” “advance,” “progress,” “position,” “maximize” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These statements include those
related to: advancement of aldafermin toward late-stage development
and other preclinical and clinical development progress; NGM’s
potential breadth of opportunities; and other statements that are
not historical fact. Because such statements deal with future
events and are based on NGM’s current expectations, they are
subject to various risks and uncertainties, and actual results,
performance or achievements of NGM could differ materially from
those described in or implied by the forward-looking statements in
this press release. These risks and uncertainties include, without
limitation, risks and uncertainties associated with: the costly and
time-consuming pharmaceutical product development process and the
uncertainty of clinical success, including risks related to failure
or delays in successfully enrolling or completing clinical studies,
the risk that the results obtained to date in NGM’s clinical trials
may not be indicative of results obtained in pivotal or other
late-stage trials, and the risk that NGM’s ongoing or future
clinical studies in humans may show that aldafermin is not a
tolerable and effective treatment for NASH patients; the evolving
effects of the COVID-19 pandemic on NGM’s business and operations,
as well as those of third parties on which NGM relies; the
time-consuming and uncertain regulatory approval process; NGM’s
reliance on third-party manufacturers for aldafermin and its other
product candidates; the sufficiency of NGM’s cash resources and
need for additional capital; and other risks and uncertainties
affecting NGM and its development programs, including those
described under the caption “Risk Factors” in NGM’s quarterly
report on Form 10-Q for the quarter ended March 31, 2020 and future
filings and reports that NGM makes from time to time with the
United States Securities and Exchange Commission. Except as
required by law, NGM assumes no obligation to update these
forward-looking statements, or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor Contact:Sylvia Wheeler and Alexandra
Santosswheeler@wheelhouselsa.comasantos@wheelhouselsa.comir@ngmbio.com |
Media Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Apr 2023 to Apr 2024